Study of a new drug combo for advanced stomach cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called ASP2138 combined with chemotherapy and pembrolizumab for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. It may help if your tumor has certain markers (CLDN18.2 and PD-L1) and you haven't had prior chemotherapy for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread.
- Your tumor must test positive for a protein called CLDN18.2, and also have a PD-L1 result from a central lab.
- You can still be physically active (ECOG score 0 or 1) and expected to live at least 12 weeks.
- You should not have had prior chemotherapy or immunotherapy for your advanced cancer, except maybe one cycle of certain chemos before joining.
- You cannot have other serious illnesses like heart disease, uncontrolled high blood pressure, bleeding problems, or active infections.
- You must agree to use effective contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests ASP2138 alone or with other cancer medicines in adults with stomach (including GEJ) or pancreatic cancer. You may be eligible if your tumor has a specific protein marker and your health tests and scan results meet safety requirements.
This trial tests a new combination of drugs for advanced stomach cancer that has spread or come back. It aims to see if adding an immune therapy and a bacterial extract to standard chemotherapy can help control the cancer better.
This trial tests a new combination of two drugs (QLS31905 and QL2107) plus standard chemotherapy for stomach cancer that has spread and tests positive for a specific marker (CLDN18.2). It's for people who haven't had treatment yet, and the goal is to see if it shrinks tumors better than standard care.
This study tests a combination of four drugs given before and after surgery for a type of stomach or throat-stomach cancer that can be removed. The drugs are adebrelimab (immunotherapy), nab-paclitaxel, oxaliplatin, and tegafur. The goal is to see if this combination works better than standard treatments.
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy for people with advanced stomach cancer that hasn't been treated yet. It compares this combination to chemotherapy with or without another immunotherapy drug, nivolumab.
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.